← All trials
NCT04474119
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 14, 2020
- Primary completion
- Aug 30, 2022
- Completion date
- Aug 30, 2023
- First posted
- Jul 16, 2020
- Last posted
- Sep 16, 2020
- Enrollment
- 516
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Alphamab Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.